Alleviating Effects Against High Intraocular Pressure by Oral Intake of Cordyceps Cicadae Mycelia

Not Applicable

Completed

• Conditions: Supplement
• Interventions: Dietary Supplement: Cordyceps Cicadae Mycelia

• Registration Number: NCT05304299
• Lead Sponsor: Han-Hsin Chang

Brief Summary

This study will investigate the effects of lowering intraocular pressure by oral intake of Cordyceps cicadae mycelia, to provide evidence-based data for high intraocular pressure relief.

Detailed Description

Study purpose This study investigated the effeicacy of oral Cordyceps cicadae mycelia for the relief of high intraocular pressure.

Subjects

1. The total recruitment of subjects is 60 people, aged between 20 to 75 years.

2. Subjects with intraocular pressure more than or equal to 21 mmHg are included, irrespective of whether on us of Taflotan (saflutan).

Methods

1. Informed consents will be obtained from subjects first. The subjects with pre-test intraocular pressure over or equal 21 mm Hg are advised to orally take two capsules containing a total of 500 mg of Cordyceps cicadae mycelia. After 90 minutes, the subjects are evaluated for intraocular pressure.

The pre-test and and post-intake intraocualr pressure and blood pressure data will be compared by paired t test for significant differences if any.

Study Timeline

• Study Start: 2020-03-10
• Primary Completion: 2021-07-31
• Study Completion: 2021-12-31
• Status Verified: 2022-03
• Study First Submitted: 2022-03-04
• Study First Submitted QC: 2022-03-22
• Last Update Submitted: 2022-03-22
• Study First Posted: 2022-03-31
• Last Update Posted: 2022-03-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

1. Age between 20 and 75 years old, regardless of gender.
2. Pre-test confirmation of high intraocular pressure.
3. Subjects should understand the trial and agree to join the project.

Exclusion Criteria

1. Age under 20 or over 75 years.
2. Use intraocular pressure lowering drugs other than Taflotan (saflutan).
3. Using beta-blockers or diuretics.
4. Being pregnant.
5. Disabled individuals with specific diseases or malfunction, for example tumours at terminal stage, blindness.
6. Loss of self-consciousness and behavioral capacity.
7. Patients with major diseases.

Withdrawal criteria All subjects may withdraw at any time without any reason. The act of withdraw does not affect rights for them to seek medical advice or treatments.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cordyceps Cicadae Mycelia only	Cordyceps Cicadae Mycelia	Only Cordyceps Cicadae Mycelia will be given.
Cordyceps Cicadae Mycelia with Taflotan (saflutan)	Cordyceps Cicadae Mycelia	Cordyceps Cicadae Mycelia with Taflotan (saflutan) will be given.

Primary Outcome Measures

Name	Time	Method
Intraocular pressure	90 minutes after given Cordyceps Cicadae Mycelia	Intraocular pressure of both eyes will be assessed
Blood pressure	90 minutes after given Cordyceps Cicadae Mycelia	Both systolic and diastolic blood pressures will be assessed

Trial Locations

Locations (1)

Han-Hsin Chang; 🇨🇳 Taichung, Taiwan